02nd week of 2013 patent applcation highlights part 47 |
Patent application number | Title | Published |
20130012543 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions. | 2013-01-10 |
20130012544 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS - The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase. | 2013-01-10 |
20130012545 | Amido-Thiophene Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 2013-01-10 |
20130012546 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES - The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2013-01-10 |
20130012547 | INSECTICIDAL COMPOUNDS - The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests. | 2013-01-10 |
20130012548 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS - This invention relates to deuterated ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof. And the pharmaceutical compositions comprising the pharmaceutically acceptable carrier and the deuterium-substituted ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof are also provided. The deuterium-substituted diphenylurea can be used in treatment or prevention of cancer and other related diseases. | 2013-01-10 |
20130012549 | Method for the Treatment, Alleviation of Symptoms of, Relieving, Improving and Preventing a Cognitive Disease, Disorder or Condition - The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition in a subject. Additionally, the invention provides use of said salt adducts for the preparation of medicaments for the improvement of cognitive functions in a healthy subject. | 2013-01-10 |
20130012550 | METHODS FOR PROGNOSIS AND MONITORING CANCER THERAPY - The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of HER-2, EGFR, VEGF, u-PA, p-PAI-1, and soluble forms thereof, as biomarkers for cancer, especially for subjects treated with sorafenib. | 2013-01-10 |
20130012551 | METHOD AND DEVICE FOR PRODUCING MICROPARTICLES OR NANOPARTICLES - The invention relates to a method for producing microparticles or nanoparticles of water-soluble and water-insoluble substances by controlled precipitation, co-precipitation and self-organization processes in microjet reactors, a solvent, which contains at least one target molecule, and a nonsolvent being mixed as jets that collide with each other in a microjet reactor at defined pressures and flow rates and thereby effect very rapid precipitation, co-precipitation or a chemical reaction, during the course of which microparticles or nanoparticles are formed. In order to create such a method, with which the particle size of the resulting microparticles or nanoparticles can be specifically controlled, it is proposed within the scope of the invention that particle size be controlled by the temperature at which the solvent and nonsolvent collide, the flow rate of the solvent and the nonsolvent and/or the amount of gas, smaller particle sizes being obtained at lower temperatures, at high solvent and nonsolvent flow rates and/or in the complete absence of gas. | 2013-01-10 |
20130012552 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more azole fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of triadimenol, bitertanol, oxpoconazole fumarate, tebuconazole, cyazofamid, pefurazoate, triflumizole, hymexazol, and etridiazole | 2013-01-10 |
20130012553 | METHODS FOR STABILIZING JOINT DAMAGE IN SUBJECTS USING XANTHINE OXIDOREDUCTASE INHIBITORS - The present invention relates to methods for preventing the progression of joint damage in a subject having hyper-uricemia and who has gout thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. Moreover, the present invention also relates to methods of preventing joint damage in a subject having hyperuricemia and who has gout by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. | 2013-01-10 |
20130012554 | OXAZOLIDINONE DERIVATIVES CONTAINING NEW BICYCLIC GROUP, HAVING ANTIBACTERIAL ACTIVITY, AND METHOD FOR TREATING PATHOGENIC BACTERIAL INFECTIONS USING THE SAME - The present invention relates to oxazolidinone derivatives containing new bicyclic group, having antibacterial activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, an antibacterial composition comprising the oxazolidinone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating an infectious disease caused by pathogen using the same. The oxazolidinone derivative or a pharmaceutically acceptable salt thereof may exhibit excellent antibacterial activity against gram positive bacteria including various resistant strains. | 2013-01-10 |
20130012555 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes - Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of IAPP or amylin fibril diseases, and the manufacture of medicaments for such treatment. | 2013-01-10 |
20130012556 | Bioactive Agrichemical Compositions and Use Thereof - Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations. | 2013-01-10 |
20130012557 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders - Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided. | 2013-01-10 |
20130012558 | Use of Fungicides for the Treatment of Fish Mycoses - Process for the protection of fish and invertebrates and all their stages of development against or for the treatment of mycoses caused by fungi of the genera | 2013-01-10 |
20130012559 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE - Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes. | 2013-01-10 |
20130012560 | KINESIN INHIBITORS AS CANCER THERAPEUTICS - The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein. | 2013-01-10 |
20130012561 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 2013-01-10 |
20130012562 | Composition for Controlling Parasites on Animals - The invention relates to novel compositions for controlling parasites on animals, comprising an N-phenylpyrazole in a formulation comprising aliphatic cyclic carbonates. | 2013-01-10 |
20130012563 | CRYSTALLINE (1R,4R)-6'-FLUORO-N,N-DIMETHYL-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXA- NE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE - Crystalline forms of (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these crystalline modifications, the use of these modifications as well as a process for the enrichment of such crystalline modifications. | 2013-01-10 |
20130012564 | SMAC Mimetic - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 2013-01-10 |
20130012565 | 4-HYDROXYBUTYRIC ACID ANALOGS - This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate. | 2013-01-10 |
20130012566 | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment of Alopecia - This invention relates to a transdermal delivery system for treating skin related diseases employing papilloma-derived protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of alopecia. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells. | 2013-01-10 |
20130012567 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. | 2013-01-10 |
20130012568 | Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy. | 2013-01-10 |
20130012569 | METHOD OF TREATMENTS RELATED TO THE FMR1 GENE - A method of treating a human to reduce the risk of malignancies or limit the spread of malignancies includes administering an FMR1 inhibitor to the human to block expression of an FMR1 gene. The FMR1 inhibitor blocks FMR1 genes in the human with at least one of two alleles with less than 26 triple CGG repeats. | 2013-01-10 |
20130012570 | GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 2013-01-10 |
20130012571 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 2013-01-10 |
20130012572 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3. | 2013-01-10 |
20130012573 | METHODS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS - A method for intracellular delivery of isolated naked nucleic acids into a biological tissue or organ, that includes (a) contacting the tissue or organ with an efficient amount of at least one active corticosteroid, and (b) contacting the tissue or organ treated in step b with an efficient amount of isolated naked nucleic acids, wherein step (a) is carried out for a period of time ranging from at least five minutes to at most two hours and being immediately followed by step (b). | 2013-01-10 |
20130012574 | Compositions and Methods for Enhanced Parvovirus Transduction - The present invention provides methods and compositions for enhanced transduction of an adeno-associated virus (AAV) vector comprising a heterologous nucleic acid of interest wherein the AAV vector genome is oversized relative to a wild type AAV genome by employing a proteasome inhibitor. | 2013-01-10 |
20130012575 | PLANT EXTRACT FROM LOW-THC CANNABIS FOR THE TREATMENT OF DISEASE - The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of | 2013-01-10 |
20130012576 | Composition for Lowering Blood Lipid and Elevating High-density Lipoprotein and Method for Manufacturing the Same - The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a | 2013-01-10 |
20130012577 | PROCESS TO OBTAIN A STANDARDIZED EXTRACT OF QUERCETIN AND 3-O-METHYLQUERCETIN FROM INFLORESCENCES OF MACELA-DO-CAMPO, A COSMETIC, PHARMACEUTICAL AND VETERINARY COMPOSITION CONTAINING EXTRACT OF MACELA-DO-CAMPO, THE USE OF THIS EXTRACT AND THE METHOD OF APPLICATION OF THE AFORESAID EXTRACT - It describes an extraction process for obtaining a standardized extract of quercetin and 3-0-methylquercetin from inflorescences of macela-do-campo ( | 2013-01-10 |
20130012578 | Novel Formulations of Bifenthrin and Enriched Cypermethrin - The present invention is directed to novel insecticidal compositions comprising bifenthrin and enriched cypermethrin, the compositions are physically stable when diluted with water. | 2013-01-10 |
20130012579 | Anti-obesity Potential of Calebin A - The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-1 (IL-1β). | 2013-01-10 |
20130012580 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2013-01-10 |
20130012581 | TREATMENT OF HEAD LICE INFESTATIONS - Techniques and apparatus for treating head lice infestations are described. Some embodiments include a nit (louse egg) detection plate that provides a surface against which irregularities of a hair of a person are more apparent to a viewer than without the detection plate. The detection plate may also include a serrated edge that is operable to separate hairs of the person for viewing over the detection plate. Other embodiments provide a method for using the detection plate to detect and remove nits from hairs of a person. The method may include placing a thin layer of hair of a person over the detection plate, detecting nits by viewing the hairs against a backdrop provided by the detection plate, and removing any detected nits. | 2013-01-10 |
20130012582 | VINYLIC MASK WITH PEEL-OFF EFFECT FOR TOPICAL USE CONTAINING HIGH CONCENTRATIONS OF RETINOIC ACID - A formulation for topical use having a filmogenic (peel-off) action for professional and home use, containing high concentrations of Retinoic acid, the method of production and use thereof in the treatment of acne, wrinkles, hyperpigmentations, psoriasis and all imperfections linked to keratinization disorders. The composition also comprises octyldodecyl octyldodecanoate, and polyvinyl alcohol. The composition is in the form of a face mask (pack). | 2013-01-10 |
20130012583 | VINYL SUBSTITUTED FATTY ACIDS - Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein. | 2013-01-10 |
20130012584 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 2013-01-10 |
20130012585 | Phenylacetic Acid Derivatives - Compounds of formula (I) pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders. | 2013-01-10 |
20130012586 | Methods of Treating Fragile X Syndrome - Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen. | 2013-01-10 |
20130012587 | Methods of Treating Autism - Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. | 2013-01-10 |
20130012588 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATEMENT OF WOUNDS - The present invention provides compositions and methods for promoting rapid healing and/or regeneration of damaged tissue resulting from a wound comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of (E)-4-carboxystyryl-4-chlorobenzylsulfone, or a functional derivative thereof, and a pharmaceutically acceptable excipient. | 2013-01-10 |
20130012589 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE - An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective α,β-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5. | 2013-01-10 |
20130012590 | SUBCUTANEOUS FAT REDUCTION - Topical dermatological preparations including one or more lipodissolving, lipolytic, or adipocyte-disrupting substances for treatment of localized adiposity can include carbamide peroxide and a terpene such as d-limonene. In some embodiments, the preparations can include carbamide peroxide as a first component and, as a second component, at least one peppermint oil terpene, peppermint oil, or a compound isolated or derived from peppermint oil. | 2013-01-10 |
20130012591 | PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES - Provided in certain embodiments herein are methods of prophylaxis of skin cancer in individuals having a heightened risk of skin cancer with a fenretinide agent. | 2013-01-10 |
20130012592 | AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF - The present invention relates to an agomelatine hydrobromide hydrate of formula I | 2013-01-10 |
20130012593 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 2013-01-10 |
20130012594 | METHOD FOR PRODUCING ASTAXANTHIN BY FERMENTATION - An object of the present invention is to provide a method for microbiologically producing astaxanthin of high concentration at low cost while suppressing production of canthaxanthin. Specifically, the present invention relates to a method for producing carotenoids including astaxanthin comprising culturing a bacterium that concurrently produces astaxanthin and canthaxanthin in a medium containing biotin, wherein a ratio of concentration of produced canthaxanthin to concentration of produced astaxanthin in a culture product after the end of culture in the medium is lower than that in a culture product after the end of culture in a biotin-free medium. | 2013-01-10 |
20130012595 | HIGH ALCOHOL CONTENT FOAMING COMPOSITIONS WITH SILICONE-BASED SURFACTANTS - This invention relates to a “high lower alcohol content” (>40% v/v of a C | 2013-01-10 |
20130012596 | POLYMERIZATION OF ALKYL(BETA-N-ALKYLAMINOPROPIONATES) FORMING UNIQUE POLYAMIDE COMPOSITIONS - A process for preparing poly N-substituted beta-alanines with the steps of: | 2013-01-10 |
20130012597 | TEMPERATURE-, PH- OR SALT CONCENTRATION-SENSITIVE SEPARATION MATERIAL AND USE THEREOF - The present invention provides a UCST-type thermoresponsive polymer compound which responds to a temperature under physiological conditions and has biofunctionality, and various uses thereof as a thermoresponsive material. Specifically, the invention provides a thermoresponsive material containing, as an active ingredient, a polymer compound represented by Formula (I) below or an addition salt thereof, the thermoresponsive material having an upper critical solution temperature in the range of 5 to 50° C. in an aqueous solution with a salt concentration of at least 1 mM and a pH in the range of 3 to 10.5: | 2013-01-10 |
20130012598 | APPARATUS AND METHODS FOR FABRICATING NANOFIBERS FROM SHEARED SOLUTIONS UNDER CONTINUOUS FLOW - Nanofibers are fabricated in a continuous process by introducing a polymer solution into a dispersion medium, which flows through a conduit and shears the dispersion medium. Liquid strands, streaks or droplets of the polymer solution are continuously shear-spun into elongated fibers. An inorganic precursor may be introduced with the polymer solution, resulting in fibers that include inorganic fibrils. The resulting composite inorganic/polymer fibers may be provided as an end product. Alternatively, the polymer may be removed to liberate the inorganic fibrils, which may be of the same or smaller cross-section as the polymer fibers and may be provided as an end product. | 2013-01-10 |
20130012599 | SURFACE TREATMENT FOR GASIFIED CONSUMABLE MATERIALS - A surface treatment for the preparation of gasified consumable materials comprising active ingredients. The surface treatment may comprise a combination of flavors, sweeteners, and active ingredients such as nutritional supplements and/or pharmaceuticals. The invention avoids the degradation of active ingredients during the manufacturing process since the active ingredients are applied to the surface of the composition and not cooked with the gasified consumable material. Methods for making and using the disclosed compositions are also within the scope of the invention. | 2013-01-10 |
20130012600 | METHOD OF TREATING ANIMAL'S EXTERIOR FOR CLEANING AND/OR INSECT REPELLENCY - A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal. The composition includes a nonionic primary surfactant comprising an ethoxylated sorbitol oleate, a nonionic secondary surfactant, and water. The nonionic secondary surfactant is selected from the group consisting of linear ethoxylated secondary alcohols, polyoxyethylene ethers, ethoxylated sorbitan monolaurates, ethoxylated fatty acid amides and ethoxylated fatty acids that contain about 7 moles to about 26 moles of ethylene oxide and comprise from about 20 to about 36 weight percent of said composition. The water is in a sufficient amount so that the nonionic primary and secondary surfactants together with the water form a gel. | 2013-01-10 |
20130012601 | Fluid Cocamide Monoethanolamide Concentrates And Methods Of Preparation - The invention is drawn to fluid concentrate formulations of fatty acid monoethanolamides comprising (a) about 71-76% by weight of one or more C8-C22 fatty acid monoethanolamides, (b) about 15-17% by weight of water, and (c) about 10-12% by weight of one or more hydrotropes, based on the fluid formulation, wherein the fluid formulation is homogeneous, pumpable and color stable at a temperature of less than 55° C. A preferred embodiment is drawn to fluid concentrate formulations of cocamide monoethanolamide (CMEA) consisting of (a) about 71-76% by weight of CMEA, (b) about 15-17% by weight of water, and (c) about 10-12% by weight of glycerol, based on the fluid formulation. Methods of preparing the fluid concentrate formulations mulations are also disclosed. The fluid concentrate formulations of fatty acid monoethanolamides are useful in the preparation of cosmetic and pharmaceutical compositions. | 2013-01-10 |
20130012602 | METHODS OF USING ZNF365 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the ZNF365 genetic locus | 2013-01-10 |
20130012603 | METHODS FOR ASSESSING THE RISK OF CARDIOVASCULAR DISEASE - The studies described herein demonstrate that γ′ fibrinogen and total fibrinogen are independent risk factors for cardiovascular disease. Further described herein is the unexpected finding that an elevated concentration of γ′ fibrinogen in combination with an elevated concentration of total fibrinogen is a significantly better predictor of cardiovascular disease risk than either marker alone. Thus, provided herein are methods of detecting a subject having cardiovascular disease, or at increased risk of developing a cardiovascular disease, by measuring both the concentration of γ′ fibrinogen and the concentration of total fibrinogen in a sample obtained from the subject. | 2013-01-10 |
20130012604 | METHODS OF USING PRDM1 GENETIC VARIANTS TO PROGNOSE, DIAGNOSE AND TREAT INFLAMMATORY BOWEL DISEASE - Methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis are disclosed. | 2013-01-10 |
20130012605 | METHOD, SYSTEM AND EQUIPMENT FOR GASIFICATION-LIQUEFACTION DISPOSAL OF MUNICIPAL SOLID WASTE - A gasification-liquefaction disposal method, system and equipment for MSW are disclosed. The method involves the MSW pretreatment of dehydrating and separating, thus reducing water and inorganic substance content of the waste. Then, the MSW is introduced into a plasma gasifier ( | 2013-01-10 |
20130012606 | FISCHER-TROPSCH SYNTHESIS - A process for the preparation of an F-T catalyst in which the presence of alkaline earth metals is minimized in the support itself and in the processing conditions, in order to provide a catalyst with an alkaline earth metal content of less than 2000 ppm. | 2013-01-10 |
20130012607 | PROTON-CONDUCTING MEMBRANE AND ITS USE - The present invention relates to novel polyazoles, a proton-conducting polymer membrane based on these polyazoles and its use as polymer electrolyte membrane (PEM) for producing membrane-electrode units for PEM-fuel cells, and also other shaped bodies comprising such polyazoles. | 2013-01-10 |
20130012608 | POLYMERIC COMPOSITIONS AND PROCESSES FOR MOLDING ARTICLES - The present invention is directed to polymeric article comprising a blend of (a) a first polymeric component; (b) a second polymeric component, the second polymeric component including a propylene elastomer or a substantially linear or linear ethylene polymer; and (c) at least one reinforcement material. The polymeric articles desirably have one or more of the following characteristics: a soft touch feel, low gloss appearance, or a high surface durability. | 2013-01-10 |
20130012609 | PROFESSIONAL GRADE ONE COMPONENT POLYURETHANE FOAM WITH NON-LIQUEFIED INERT PROPELLANT - A one-component-foam formulation contains a propellant in a concentration range of from 5 to 35 weight-percent of total formulation weight and contains at least 50 weight-percent non-liquefied inert gases based on total propellant weight, a polyol, a silicone glycol copolymer and less than 0.01 weight-percent of a cell opener based on polyol weight. An article contains five liters or more of the one-component-foam formulation within a container compressed to a pressure of at least 15 atmospheres pressure. A method for dispensing the one-component foam formulation includes providing the article and expelling the formulation from the container through a dispensing means onto a substrate and allowing the formulation to expand into a stable polymeric foam having a density of 45 kilograms per cubic meter or less. | 2013-01-10 |
20130012610 | LIGNIN AND OTHER PRODUCTS ISOLATED FROM PLANT MATERIAL, METHODS FOR ISOLATION AND USE, AND COMPOSITIONS CONTAINING LIGNIN AND OTHER PLANT-DERIVED PRODUCTS - Lignin polymers having distinctive properties, including a generally high molecular weight and generally homogeneous size distribution, as well as preservation of native reactive side groups, are isolated by solvent extraction of plant materials. Methods for isolation of lignin polymers, and for use of the isolated lignin polymers are disclosed. Compositions containing lignin isolated from plant materials, such as carbon fiber composites, resins, adhesive binders and coatings, polyurethane-based foams, rubbers and elastomers, plastics, films, paints, nutritional supplements, food and beverage additives are disclosed. Xylose and xylose derivatives, furfural, fermentable sugars, cellulose and hemi-cellulose products may be used directly or further processed. The lignin polymers and other plant-derived products disclosed herein may be produced in abundance at low cost, and may be used as substitutes for feedstocks originating from fossil fuel or petrochemical sources in the manufacture of various products. | 2013-01-10 |
20130012611 | SYNERGISTS - Compounds of formula (I): wherein Ar represents an, optionally substituted, aryl or heteroaryl group, R represents an, optionally substituted, aryl or heteroaryl group, an optionally substituted straight or branched chain C | 2013-01-10 |
20130012612 | METHOD FOR GENERATING BIOCOMPATIBLE THREE-DIMENSIONAL OBJECTS OR SURFACES BY LASER IRRADIATION, SUCH OBJECTS, THE USE THEREOF AND STARTING MATERIALS FOR THE METHOD - The present invention pertains to a process for producing three-dimensional, self-supporting and/or substrate-supported formed pieces or structures on surfaces by means of site-selective solidification of a liquid to pasty, organic or organically modified material within a bath consisting of this material by means of two- or multiphoton polymerization, whereby the material has at least one compound that has both an organic radical polymerizable via two-photon or multiphoton polymerization and a biocompatible, biodegradable or bioresorbable group, and/or wherein the bath material additionally contains groups or radicals, which are available for an inorganic crosslinking or which are already inorganically crosslinked, providing that both an organic radical polymerizable via two-photon or multiphoton polymerization and a biocompatible, biodegradable or bioresorbable group must be contained in the material. The formed pieces or surface structures according to the present invention are suitable as matrices for binding live cells, which can be multiplied after that or stimulated for the production of specific substances. They can be used, e.g., as an extracorporeal [sic—Tr.Ed.] matrix or as an implant. | 2013-01-10 |
20130012613 | METHOD FOR SYNTHESIZING CALIXARENE AND/OR CYCLODEXTRIN COPOLYMERS, TERPOLYMERS AND TETRAPOLYMERS, AND USES THEREOF - A method synthesizes a composition of polymers, copolymers, terpolymers and tetrapolymers. The composition may be made by combining in a reaction chamber, a crosslinking agent and one or more of a calix[n]arene, cyclodextrin, a mixture of a plurality of calix[n]arenes, different cyclodextrins, derivatives of calix[n]arenes, and derivatives of cyclodextrins, stirring the mixture, making a solid residue using microwaves, washing the solid residue, drying some of the wash, filtering some of the wash, and drying the resulting filtered solution. The composition may include alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, the derivatives or corresponding mixtures thereof, and/or calix[n]arene(s) and/or of calix[n]arene derivative(s) and/or a mixture of two or more different calix[n]arenes selected from calix[n]arenes (n=4-20) and/or the derivatives thereof. The method has application to pharmaceuticals, human medicine, veterinary medicine, chemistry, separation chemistry, environmental, electronics, biological, diagnostics, phytosanitation, medicinal food, agri-food, cosmetics, the nutraceutical field, and in the field of molecular imprints (MIP). | 2013-01-10 |
20130012614 | POLYMERIZABLE ISOCYANURATE MONOMERS AND DENTAL COMPOSITIONS - Polymerizable isocyanurate monomers and dental compositions are described. A hardenable dental composition is described comprising at least one isocyanurate monomer that is a stable liquid at about 25° C. The isocyanurate monomer comprises at least one divalent linking group bonded to a nitrogen atom of a trivalent isocyanuric acid ring, wherein the divalent linking group comprises a moiety selected from ester, thioester, ether, or thioether, and combinations of such moieties and a terminal ethylenically unsaturated polymerizable group. | 2013-01-10 |
20130012615 | ONE-PART DENTAL ADHESIVE COMPOSITION - The present invention provides a one-part dental adhesive composition that exhibits excellent adhesive property and bond durability to a tooth structure (particularly dentin) and has high stability to ambient light, in which respective components have been mixed uniformly. The present invention is a one-part dental adhesive composition including a polymerizable monomer (A) having an acidic group, a polymerizable monomer (B) having a fluorocarbon group represented by the general formula (1), water (C), and a polymerization initiator (D). A content of the polymerizable monomer (A) having an acidic group is 5.5 to 35 parts by weight in 100 parts by weight of the total amount of polymerizable monomers. (In the formula, R | 2013-01-10 |
20130012616 | RUBBER COMPOSITION FOR TIRE, AND PNEUMATIC TIRE - The present invention provides a rubber composition for a tire which can achieve both high levels of fuel economy and abrasion resistance, as well as excellent wet grip performance; and a pneumatic tire produced using the rubber composition. The rubber composition for a tire includes a rubber component that includes 5% by mass or more of a modified styrene butadiene rubber containing a constitutional unit derived from a specific nitrogen-containing compound in a main chain, based on 100% by mass of the rubber component; silica; and a compound represented by the following formula (I): | 2013-01-10 |
20130012617 | POLYMERIC COMPOSITIONS CONTAINING MICROSPHERES - Disclosed herein is a composition having a thermoset polymer and a plurality of hollow microsphere homogenously dispersed in the composition. The polymer is a cyanate ester thermoset, a phthalonitrile thermoset, a crosslinked acetylene thermoset, or a hydrosilation thermoset. Also disclosed herein is a method of: providing a thermosetting compound; adding microspheres to the thermosetting compound; and mixing the thermosetting compound while initiating crosslinking of the thermosetting compound. | 2013-01-10 |
20130012618 | RESIN COMPOSITION, POLYMER, CURED FILM AND ELECTRONIC PART - Provided are a resin composition capable of forming a cured film excellent in elongation properties; a polymer suitable as a component contained in the composition; a cured film formed from the composition; and an electronic part including the cured film. The resin composition includes (A) a polymer containing a structural unit represented by the formula (a1) and a structural unit represented by the formula (a2); and (F) a solvent, | 2013-01-10 |
20130012619 | EPOXY RESIN COMPOSITION FOR ELECTRONIC COMPONENT ENCAPSULATION AND ELECTRONIC COMPONENT DEVICE USING THE SAME - The present invention relates to an epoxy resin composition for electronic component encapsulation, including the following components (A) to (D): (A) an epoxy resin; (B) a curing agent: an allylated phenol resin containing a structural unit (1) shown below and a structural unit (2) shown below, in which a molar ratio [structural unit (1)/[structural unit (1)+structural unit (2)]×100] of the structural unit (1) to a total amount of the structural unit (1) and the structural unit (2) is from 40 to 100%; (C) a curing accelerator; and (D) an inorganic filler, in which the allylated phenol resin as the component (B) has a glass transition temperature of −5° C. to 70° C. as measured by a differential scanning calorimetry (DSC) method: | 2013-01-10 |
20130012620 | CURING AGENTS FOR EPOXY RESINS - The present invention relates to curatives for epoxy resins, and compositions (e.g. adhesives) containing such resins cured using the same methods of preparation and uses therefor. More specifically, the present invention relates to hybrid curatives for epoxy resins comprising both aromatic amine, phenol and/or phenyl ester moieties. A further aspect of the current invention relates to new imidazole catalysts that possess a combination of excellent cure latency as well as low cure temperature onset. | 2013-01-10 |
20130012621 | THERMOSETTING RESIN COMPOSITION, B-STAGE HEAT CONDUCTIVE SHEET, AND POWER MODULE - Provided is a thermosetting resin composition including an inorganic filler and a thermosetting resin matrix component, in which the inorganic filler includes secondary sintered particles each formed of primary particles of scaly boron nitride, and at least some of the secondary sintered particles each have a maximum cavity diameter of 5 μm to 80 μm. The thermosetting resin composition can be used for providing a heat conductive sheet in which electrical insulation property is kept by controlling where the defects such as voids and cracks occur and their size, and which has excellent heat conductivity. | 2013-01-10 |
20130012622 | INK FOR INKJET COMPUTER-TO-PLATE AND PREPARATION METHOD OF THE SAME - An ink for inkjet computer-to-plate and a preparation method of the same are provided. Calculated in mass percentage based on the total mass of the ink, the ink comprises 10%˜30% of cross-linkable resin, 10%˜35% of solvent with a low boiling point, 5%˜30% of poor solvent with a high boiling point and 5%˜75% of bulk solvent. The preparation method comprises the following steps: mixing the above components and agitating at room temperature; after the cross-linkable resin is dissolved, ball milling and filtrating to remove insoluble substance and/or impurities in the liquid obtained by the ball milling. The ink can be formed into an image by printing on the treated surface of aluminum plate using ink jetprinter, and after heat cured, it can form an image with a high resolution and be used to print directly on machine, thus reducing post treatment process and obtaining the plate of ink jettingdirect plate-making. | 2013-01-10 |
20130012623 | METHODS AND MANUFACTURES RELATED TO ENCAPSULATION OF SILICA AEROGEL POWDER - Encapsulation of silica aerogel powder. At least some of the illustrative embodiments are directed to methods including encapsulating silica aerogel powder. The encapsulating may include: providing the silica aerogel powder in a reaction chamber; supplying a monomer to the reaction chamber; creating an activated form of the monomer; and associating at least a portion the activated monomer with the silica aerogel powder. | 2013-01-10 |
20130012624 | METHOD FOR PRODUCING SEMICONDUCTOR ENCAPSULATING RESIN COMPOSITION AND PULVERIZING APPARATUS - A pulverizing apparatus is a gas stream type pulverizing apparatus. The pulverizing apparatus has a pulverizing unit for pulverizing a composition, a cooling device, a high-pressure air generating device and a collecting unit for receiving the pulverized composition. The chamber has a bottom portion, an outlet formed in the bottom portion for discharging the pulverized first composition therethrough and a wall portion formed in the bottom portion so as to surround the outlet. A plurality of first nozzles and a second nozzle are provided on a side portion of the chamber and a tubular supply unit is provided on an upper portion of the second nozzle. The gas pressure supplied into the chamber is 0.3 MPa or more, the gas temperature is 20° C. or less, and the humidity of the gas is 40% RH or less. | 2013-01-10 |
20130012625 | STRAIN HARDENING BRITTLE MATRIX COMPOSITES WITH HIGH STRENGTH AND HIGH TENSILE DUCTILITY - A new class of ultra-high performance concrete with very high strength and very high tensile ductility (High Strength High Ductility Concrete) is provided that represents the culmination of two high performance cement-based composite systems, namely those of very high strength, and those of very high tensile ductility into a single composite system. The integration of high strength and ductility has been attained via the adoption of micromechanical analysis and design of fiber reinforced brittle matrix composites. In doing so, the new High Strength High Ductility Concrete material dramatically increases the energy absorption capabilities of structural systems employing this material, making it a very good candidate material where hurricanes, earthquake, impact and blast loads are a concern. | 2013-01-10 |
20130012626 | RESIN-TREATED PIGMENT, METHOD FOR PRODUCING THE PIGMENT, AND PIGMENT DIPERSION - Disclosed are a resin-treated pigment characterized in that the resin-treated pigment comprises a pigment and a polymer of an unsaturated bond-containing monomer, a weight ratio of the pigment to the polymer (pigment:polymer) is from 50 to 95 to from 5 to 50, and the polymer is a block copolymer comprising from 5 to 70 mass % of an addition-polymerizable monomer having a UV-absorbing group; a production process of the resin-treated pigment; and a pigment dispersion using the resin-treated pigment. | 2013-01-10 |
20130012627 | 2K waterborne polyurethane coating system and methods thereof - The present system is a waterborne coating system comprising a two-part aqueous polyurethane coating which provides for building solvent based equivalent film thickness without foaming or gassing while retaining properties of little or no volatile organic compound (VOC) or hazardous air pollutant (HAPs) emission. A blend of various acrylic copolomers neutralized in water based emulsion and combined with an emulsified polyester polyol provides the resin system allowing adhesion to a various number of substrates. In at least one embodiment, the acrylic polyol is an acrylic copolymer having the hydrophilizing groups and isocyanate-reactive functionality incorporated into the polymer via appropriate monomer selection or subsequent modification. | 2013-01-10 |
20130012628 | POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE - The invention is to provide a polycarbonate resin composition having excellent light resistance, transparency, hue, heat resistance, thermal stability, and mechanical strength. The invention relates to a polycarbonate resin composition which includes a polycarbonate resin at least containing structural units derived from a dihydroxy compound having the portion represented by the following general formula (1) as part of the structure thereof, the polycarbonate resin composition giving a molded object which has a haze of 12 or less as measured in accordance with a specific manner. (The case where the portion represented by the general formula (1) is part of —CH | 2013-01-10 |
20130012629 | META-TYPE WHOLLY AROMATIC POLYAMIDE FIBER - There is provided a novel meta-type wholly aromatic polyamide fiber which has a high breaking strength and can inhibit coloration or discoloration under high temperatures, while retaining latent properties of the meta-type wholly aromatic polyamide fiber, such as heat resistance and flame retardancy. Components or conditions of a coagulation bath are appropriately controlled so as to give a dense coagulation state having no skin-core structure, plastic stretching is performed within a specific ratio, and further, subsequent heat stretching conditions are made proper, thereby obtaining a meta-type wholly aromatic polyamide fiber containing substantially no layered clay mineral, in which the amount of solvent remaining in the fiber is 1.0% by mass or less based on the whole fiber, and the breaking strength of the fiber is from 4.5 to 6.0 cN/dtex. | 2013-01-10 |
20130012630 | GRANULATED RESIN ADDITIVE COMPOSITION - The present invention provides a granulated resin additive composition which comprises an aromatic metal phosphate salt and a phenolic antioxidant and, when blended in a resin, allows the resulting resin composition to have excellent mechanical strengths and transparency. The granulated resin additive composition is characterized by comprising a phosphate salt compound represented by the Formula (I): | 2013-01-10 |
20130012631 | FLAME-RETARDANT POLYLACTIC ACID BASED RESIN COMPOSITION, MOLDED ARTICLE THEREOF AND METHOD FOR PRODUCING MOLDED ARTICLE - A polylactic acid based resin composition includes a polylactic acid based resin (A), a flame retardant (B) and a carbodiimide compound (C), the flame retardant (B) including at least a phosphorus compound (b1) having a phosphaphenanthrene skeleton and a hydroxy group, and the carbodiimide compound (C) including at least an aliphatic carbodiimide. | 2013-01-10 |
20130012632 | AQUEOUS DISPERSION LIQUID AND PROCESS FOR PRODUCING THE SAME, AND LAYERED BODY - Provided is a process for producing an aqueous dispersion liquid, wherein, in an aqueous medium, an ethylene/(meth)acrylic acid copolymer (A) containing (meth)acrylic acid-derived constituent units in an amount of 8% by mass or more is neutralized by using an alkanolamine (B) and dispersed. The above-described alkanolamine (B) is preferably represented by general formula (1) below. | 2013-01-10 |
20130012633 | HYBRID COMPOSITION AND MEMBRANE BASED ON SILYLATED HYDROPHILIC POLYMER - The present invention provides a method for making an organic-inorganic hybrid composition membrane comprising the steps of preparing a sol comprising at lease one silylated polyamine, casting the sol onto a surface and drying the sol to form the organic-inorganic hybrid composition membrane. The hybrid composition membrane may be used for capturing and separating CO | 2013-01-10 |
20130012634 | Polymer compositions comprising core/shell particles - A polymer composition comprising a polymer and a core/shell particle with improved properties and a photovoltaic module comprising such polymer composition. The polymer in the polymer composition may be selected from the group consisting of polyarylene polyethers having a specific composition, polyimides having a specific composition, and halogenated polymers. | 2013-01-10 |
20130012635 | CURED THERMOPLASTIC POLYMER FOR SHAPE MEMORY MATERIAL AND ARTICLES FORMED THEREFROM - A thermoplastic material comprises the cure product of a thermoplastic polymer having a thermal decomposition temperature greater than or equal to about 200° C., the thermoplastic polymer being cured at a temperature of about 200° C. to about 400° C., for a total time of less than or equal to 200 hours. An article is formed from the thermoplastic material. | 2013-01-10 |
20130012636 | DISPERSIONS OF SILICON NANOPARTICLES - Inorganic particle/polymer composites are described that involve chemical bonding between the elements of the composite. In some embodiments, the composite composition includes a polymer having side groups chemically bonded to inorganic particles. Furthermore, the composite composition can include chemically bonded inorganic particles and ordered copolymers. Various electrical, optical and electro-optical devices can be formed from the composites. | 2013-01-10 |
20130012637 | IMPROVED PROCESS FOR FORMING POLYARYLENE SULFIDE FIBERS - An improved process for forming polyarylene sulfide fibers is provided. The process comprises forming at least one fiber from a polymer melt comprising a polyarylene sulfide and at least one tin additive comprising a branched tin(II) carboxylate. Using such a melt, the fiber forming continuity is improved compared to that of the native polyarylene sulfide melt processed under the same conditions. | 2013-01-10 |
20130012638 | METHODS OF DECREASING VISCOSITY OF A POLYARYLENE SULFIDE-CONTAINING POLYMER MELT - This invention relates to methods for decreasing the complex viscosity of a polyarylene sulfide polymer melt while maintaining the molecular weight of the polyarylene sulfide with time. This invention also relates to polymer melt compositions comprising a polyarylene sulfide, wherein the complex viscosity of the composition is decreased relative to the complex viscosity of the native polyarylene sulfide measured under the same conditions, and the weight average molecular weight of the polyarylene sulfide is maintained. The methods of decreasing the complex viscosity of a polyarylene sulfide-containing polymer melt, and the polymer melt compositions so obtained, are useful in processes to produce fibers, films, nonwovens, and molded parts from polyarylene sulfides. | 2013-01-10 |
20130012639 | ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE POWDER COMPOSITION - The invention is directed to an ultra high molecular weight polyethylene powder composition comprising precipitated magnesium salt of a carboxylic acid. The process for the addition of the precipitated magnesium salt of a carboxylic acid to ultra high molecular weight polyethylene takes place by adding a master fluff comprising virgin ultra high molecular weight polyethylene and precipitated magnesium salt of a carboxylic acid to virgin ultra high molecular weight polyethylene. The precipitated magnesium salt of a carboxylic acid results in an improved corrosion behaviour and in improved colour characteristics. Furthermore the free flowing properties of the powder are positively influenced by this additive. | 2013-01-10 |
20130012640 | HEAT-SHRINKABLE POLYESTER-BASED SINGLE-LAYER FILM - The present invention relates to a heat-shrinkable polyester-based single-layer film which has superior shrinkability and color, and thus provides aesthetic enhancement to the product to which the film is attached when the film is printed. Therefore, the polyester-based single-layer film of the present invention can be valuably used as a label film as it can replace labels made of paper, and can be easily peeled off by means of hot water, thus contributing to the recycling of bottles. | 2013-01-10 |
20130012641 | MOLDING MATERIAL HAVING VIBRATION-DAMPING PROPERTY AND MOLDED ARTICLE - A molding material containing a vibration damping material composed of a resin composition of a polyester resin composed of a dicarboxylic acid component constituent unit and a diol component constituent unit having titanium dioxide and a mica flake dispersed therein; and a modifier for improving fluidity. A ratio of a total sum of a number of the dicarboxylic acid component having an odd carbon atom number in a main chain thereof and a number of the diol component having an odd carbon atom number in a main chain thereof to a total sum of a number of all dicarboxylic acid components and a number of all diol components is in the range of from 0.5 to 1.0; in the vibration damping material, a mass ratio of the polyester resin, the titanium dioxide and the mica flake is in the range of (15 to 40):(5 to 30):(30 to 80). | 2013-01-10 |
20130012642 | Heterophasic Polyolefin Composition - Polymer composition suitable for ABS styrenic resin replacement where high dimensional stability and a good esthetical appearance is required, comprising a polymer blend (A), comprising 60-80% by weight, of a crystalline propylene homo or copolymer (A1) (MFR <50 g/10 min); and 20-40% by weight, of copolymer(s) of ethylene (A2). Said polymer blend (A) having values of MFR up to 30 g/10 min; the amounts of (A1) and (A2) being referred to the total weight of the polymer blend (A). The polymer composition further comprises 20-40% by weight, of a talc mineral filler (B); the amount of components (B) being referred to the total weight of the composition. Optionally the polymer composition further comprises 1-15% by weight, of an elastomeric polymer (C) different from (A2), having a hardness (Shore A, ASTM D-2240) value equal to or lower than 80 points; the amount of components (C) being referred to the total weight of the composition. | 2013-01-10 |